ABCD position paper on insulin pumps

Practical Diabetes International

Volumn 23, Issue 9, 2006, Pages 395-400

  Hammond, Peter ^a   Boardman, Shirine ^b,d   Greenwood, Richard ^c  

^a HARROGATE DISTRICT HOSPITAL   (United Kingdom)

^b SOUTH WARWICKSHIRE NHS FOUNDATION TRUST   (United Kingdom)

^c Association of British Clinical Diabetologists   (United Kingdom)

^d WARWICK HOSPITAL   (United Kingdom)

Author keywords

ABCD; Hypoglycaemia; Insulin pumps; Position statement

Indexed keywords

HEMOGLOBIN A1C; INSULIN; INSULIN GLARGINE; ISOPHANE INSULIN;

ARTICLE; CLINICAL EFFECTIVENESS; CLINICAL TRIAL; CONTINUOUS INFUSION; COST EFFECTIVENESS ANALYSIS; DIABETIC KETOACIDOSIS; DRUG CONTRAINDICATION; DRUG COST; DRUG EFFICACY; DRUG INDICATION; DRUG SUBSTITUTION; EVIDENCE BASED MEDICINE; GLYCEMIC CONTROL; HEALTH CARE COST; HUMAN; HYPOGLYCEMIA; INSULIN BLOOD LEVEL; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN INFUSION; INSULIN PUMP; INSULIN RESISTANCE; INSULIN TREATMENT; INTERMETHOD COMPARISON; META ANALYSIS; NON INSULIN DEPENDENT DIABETES MELLITUS; PATIENT SATISFACTION; PRACTICE GUIDELINE; PREGNANCY DIABETES MELLITUS; QUALITY ADJUSTED LIFE YEAR; QUALITY OF LIFE; RISK REDUCTION; SYSTEMATIC REVIEW; TREATMENT INDICATION; UNITED KINGDOM;

EID: 33845911528     PISSN: 13578170     EISSN: 1528252X     Source Type: Journal    
DOI: 10.1002/pdi.1023     Document Type: Article

References (37)

1. NICE Technology Appraisal No 57: Guidance on the use of continuous subcutaneous insulin infusion for diabetes. London: National Institute for Clinical Excellence, February 2003.
2. Pickup J, Mattock M, Kerry S. Glycaemic control with continuous subcutaneous insulin infusion compared with intensive insulin injections in patients with type 1 diabetes: meta-analysis of randomised controlled trials. BMJ 2002; 324: 1-6.
3. Hoogma RPML, Hammond PJ, Gomis R, et al. Comparison of the effects of continuous subcutaneous insulin infusion (CSII) and NPH-based multiple daily insulin injections (MDI) on glycaemic control and quality of life: results of the 5-nations trial. Diabetic Med 2006; 23: 141-147.
4. Colquitt J, Royle P, Waugh N. Are analogue insulins better than soluble in continuous subcutaneous insulin infusion? Results of a meta-analysis. Diabetic Med 2003; 20: 863-866.
5. Weissberg-Benchell J, Antisdel-Lomaglio J, Seshadri R. Insulin Pump Therapy: A meta-analysis. Diabetes Care 2003; 26: 1079-1087.
6. Pickup JC, Kidd J, Burmiston S, et al. Effectiveness of continuous subcutaneous insulin infusion in hypoglycaemia-prone type 1 diabetes. Pract Diabetes Int 2005; 22: 10-14.
7. 1c in those using it for at least 12 months. Diabetic Med 2005; 22(Suppl 2): P89.
8. Rodrigues IAS, Reid HA, Ismail K, et al. Indications and efficacy of continuous subcutaneous insulin infusion (CSII) therapy in Type 1 diabetes mellitus: a clinical audit in a specialist service. Diabetic Med 2005; 22: 842-849.
9. 1c. Diabetes Care 2004; 27: 2590-2596.
10. Hirsch IB, Bode BW, Garg S, et al. Continuous subcutaneous insulin infusion (CSII) of insulin aspart versus multiple daily injection of insulin aspart/insulin glargine in type 1 diabetic patients previously treated with CSII. Diabetes Care 2005; 28: 533-538.
11. Doyle EA, Weinzimer SA, Steffen AT, et al. A randomized, prospective trial comparing the efficacy of continuous subcutaneous insulin infusion with multiple daily injections using insulin glargine. Diabetes Care 2004; 27: 1554-1558.
12. Fahlen M, Eliasson B, Oden A. Optimization of basal insulin delivery in Type 1 diabetes: a retrospective study on the use of continuous subcutaneous insulin infusion and insulin glargine. Diabetic Med 2004; 22: 382-386.
13. Raskin P, Bode BW, Marks JB, et al. Continuous subcutaneous insulin infusion and multiple daily injection therapy are equally effective in type 2 diabetes: a randomized, parallel-group, 24-week study. Diabetes Care 2003; 26: 2598-2603.
14. Herman WH, Ilag LL, Johnson SL, et al. A clinical trial of continuous subcutaneous insulin infusion versus multiple daily injections in older adults with type 2 diabetes. Diabetes Care 2005; 28: 1568-1573.
15. Wainstein J, Metzger M, Boaz M, et al. Insulin pump therapy vs. multiple daily injections in obese Type 2 diabetic patients. Diabetic Med 2005; 22: 1037-1046.
16. Pouwels M-JJ, Tack CJ, Hermus AR, et al. Treatment with intravenous insulin followed by continuous subcutaneous insulin infusion improves glycaemic control in severely resistant type 2 diabetic patients. Diabetic Med 2003; 20: 76-79.
17. Hammond P. Continuous subcutaneous insulin infusion: short-term benefits apparent, long-term benefits speculative. Br J Diabetes Vasc Dis 2004; 4: 104-108.
18. Diabetes Control and Complications Trial Research Group. Implementation of treatment protocols in the Diabetes Control and Complications Trial. Diabetes Care 1995; 18: 371-376.
19. The Kroc Collaborative Study Group. Diabetic retinopathy after two years of intensified insulin treatment. Follow-up of the Kroc Collaborative Study. JAMA 1988; 260(1): 37-41.
20. De Vries JH, Snoek FJ, Kostense PJ, et al. A randomized trial of continuous subcutaneous insulin infusion and intensive injection therapy in type 1 diabetes for patients with long-standing poor glycemic control. Diabetes Care 2002; 25(11): 2074-2080.
21. Kamoi K, Miyakoshi M, Maruyama R. A quality-of-life assessment of intensive insulin therapy using insulin lispro switched from short-acting insulin and measured by an ITR-QOL questionnaire: a prospective comparison of multiple daily insulin injections and continuous subcutaneous insulin infusion. Diabetes Res Clin Pract 2004; 64: 19-25.
22. Linkeschova R, Raoul M, Bott U, et al. Less severe hypoglycaemia, better metabolic control, and improved quality of life in Type 1 diabetes mellitus with continuous subcutaneous insulin infusion (CSII) therapy; an observational study of 100 consecutive patients followed for a mean of 2 years. Diabetic Med 2002; 19: 746-751.
23. Weintrob N, Benzaquem H, Galatzer A, et al. Comparison of continuous subcutaneous insulin infusion and multiple daily injection regimens in children with Type 1 diabetes: a randomised open crossover trial. Pediatrics 2003; 112: 559-564.
24. Scuffham P, Carr L. The cost-effectiveness of continuous subcutaneous insulin infusion compared with multiple daily injections for the management of diabetes. Diabetic Med 2003; 20: 586-593.
25. Roze S, Valentine WJ, Zakrzewska KE, et al. Health-economic comparison of continuous insulin infusion with multiple daily injection for the treatment of Type 1 diabetes in the UK. Diabetic Med 2005; 22: 1239-1245.
26. Gabbe SG, Holing E, Temple P, et al. Benefits, risks, costs, and patient satisfaction associated with insulin pump therapy for the pregnancy complicated by type 1 diabetes. Am J Obstet Gynecol 2000; 182: 1283-1291.
27. Mancuso S, Caruso, Lanzone A, et al. Continuous subcutaneous insulin infusion (CSII) in pregnant diabetic women. Acta Endocrinol 1986; 277: 112-116.
28. Feldberg D, Dicker D, Samuel N, et al. Intrapartum management of insulin-dependent diabetes mellitus (IDDM) gestants. A comparative study of constant intravenous insulin infusion and continuous subcutaneous insulin infusion pump (CSIIP). Acta Obstet Gynecol Scand 1988; 67: 333-338.
29. Hayat H, Carling J, Dudley S, et al. Benefits of pump therapy in diabetic pregnancy. Diabetic Med 2005; 22(Suppl 2): P279.
30. Carta Q, Meriggi E, Trossarelli GF, et al. Continuous subcutaneous insulin infusion versus intensive conventional insulin therapy in type I and type II diabetic pregnancy. Diabet et Metab 1986; 12: 121-129.
31. Lapolla A, Dalfra MG, Masin M, et al. Analysis of outcome of pregnancy in type 1 diabetics treated with insulin pump or conventional insulin therapy. Acta Diabetol 2003; 40: 143-149.
32. Diabetes Control and Complications Trial Research Group. Pregnancy outcomes in the Diabetes Control and Complications Trial. Am J Obstet Gynecol 1996; 174: 1343-1353.
33. Fox LA, Buckloh LM, Smith SD, et al. A randomized controlled trial of insulin pump therapy in young children with Type 1 diabetes. Diabetes Care 2005; 28: 1277-1281.
34. Boland EA, Grey M, Oesterle A, et al. Continuous subcutaneous insulin infusion. A new way to lower risk of severe hypoglycaemia, improve metabolic control, and enhance coping in adolescents with type 1 diabetes. Diabetes Care 1999; 22: 1779-1784.
35. McMahon SK, Airey FL, Marangou DA, et al. Insulin pump therapy in children and adolescents: improvements in key parameters of diabetes management including quality of life. Diabetic Med 2005; 22: 92-96.
36. Weinzimer SA, Ahern JH, Doyle EA, et al. Persistence of benefits of continuous subcutaneous insulin infusion in very young children with type 1 diabetes: a follow-up report. Pediatrics 2004; 114: 1601-1605.
37. Steindel BS, Roe TR, Costin G, et al. Continuous subcutaneous insulin infusion (CSII) in children and adolescents with chronic poorly controlled type 1 diabetes mellitus. Diab Res Clin Pract 1995; 27: 199-204.